Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Urinary Incontinence - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Urinary Incontinence - Pipeline Review, H1 2015', provides an overview of the Urinary Incontinence's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Incontinence and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Urinary Incontinence pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Urinary Incontinence Overview 8 Therapeutics Development 9 Pipeline Products for Urinary Incontinence - Overview 9 Pipeline Products for Urinary Incontinence - Comparative Analysis 10 Urinary Incontinence - Therapeutics under Development by Companies 11 Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes 12 Urinary Incontinence - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Urinary Incontinence - Products under Development by Companies 16 Urinary Incontinence - Products under Investigation by Universities/Institutes 17 Urinary Incontinence - Companies Involved in Therapeutics Development 18 Allergan, Inc. 18 Astellas Pharma Inc. 19 Beech Tree Labs, Inc. 20 Cook MyoSite Incorporated 21 Evotec AG 22 FemmePharma Global Healthcare, Inc. 23 Innovacell Biotechnologie AG 24 Recordati S.p.A. 25 TheraVida, Inc. 26 Urinary Incontinence - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (mirabegron + solifenacin succinate) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 (tolterodine + pilocarpine) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 BTL-ui - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Cell Therapy for Urinary Incontinence - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ICES-13 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 oxybutynin hydrochloride - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Prof-003 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 REC-1819 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 senrebotase - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Stem Cell Therapy for CAD, Urinary Incontinence and Fecal Incontinence - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 THVD-202 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Urinary Incontinence - Recent Pipeline Updates 51 Urinary Incontinence - Dormant Projects 54 Urinary Incontinence - Discontinued Products 57 Urinary Incontinence - Product Development Milestones 59 Featured News & Press Releases 59 Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 59 Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence 59 Nov 06, 2012: Beech Tree Labs Completes Phase IIa Urinary Incontinence Clinical Trial Using UISH001 60 Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 60 Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients 61 Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency 61 Aug 30, 2011: Innovacell passes a further milestone 62 May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 63 Apr 13, 2011: Beech Tree Labs Initiates Urinary Incontinence Trial 63 Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 64 Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 65 Disclaimer 66
List of Tables Number of Products under Development for Urinary Incontinence, H1 2015 9 Number of Products under Development for Urinary Incontinence - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Urinary Incontinence - Pipeline by Allergan, Inc., H1 2015 18 Urinary Incontinence - Pipeline by Astellas Pharma Inc., H1 2015 19 Urinary Incontinence - Pipeline by Beech Tree Labs, Inc., H1 2015 20 Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H1 2015 21 Urinary Incontinence - Pipeline by Evotec AG, H1 2015 22 Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H1 2015 23 Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2015 24 Urinary Incontinence - Pipeline by Recordati S.p.A., H1 2015 25 Urinary Incontinence - Pipeline by TheraVida, Inc., H1 2015 26 Assessment by Monotherapy Products, H1 2015 27 Assessment by Combination Products, H1 2015 28 Number of Products by Stage and Target, H1 2015 30 Number of Products by Stage and Mechanism of Action, H1 2015 32 Number of Products by Stage and Route of Administration, H1 2015 34 Number of Products by Stage and Molecule Type, H1 2015 36 Urinary Incontinence Therapeutics - Recent Pipeline Updates, H1 2015 51 Urinary Incontinence - Dormant Projects, H1 2015 54 Urinary Incontinence - Dormant Projects (Contd..1), H1 2015 55 Urinary Incontinence - Dormant Projects (Contd..2), H1 2015 56 Urinary Incontinence - Discontinued Products, H1 2015 57 Urinary Incontinence - Discontinued Products (Contd..1), H1 2015 58
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.